Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) (SAVAL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06088381 |
|
Recruitment Status :
Recruiting
First Posted : October 18, 2023
Last Update Posted : April 23, 2024
|
Sponsor:
University of Maryland, Baltimore
Information provided by (Responsible Party):
Jason Molitoris, MD PhD, University of Maryland, Baltimore
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 18, 2025 |
| Estimated Study Completion Date : | October 18, 2027 |